Djibouti Health Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Djibouti Health Journal.

Press releases published on June 22, 2026

3 hours ago

Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition

Indeterminate GlobeNewswire

3 hours ago

GuideAI Health Receives FDA 510(k) Clearance for VascularAssist Occlusion Triage

Indeterminate GlobeNewswire

3 hours ago

Autonomix Medical Announces Standalone Neural Sensing Program with Evidence of Real-Time Renal Nerve Activity Change

Indeterminate GlobeNewswire

3 hours ago

Hyperion DeFi and Blockdaemon Partner to Expand Institutional Hyperliquid Staking Infrastructure

Indeterminate GlobeNewswire

3 hours ago

Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.

Indeterminate GlobeNewswire

3 hours ago

Nasus Pharma to Participate in the Zacks Life Sciences Investor Forum

Indeterminate GlobeNewswire

3 hours ago

Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

Indeterminate GlobeNewswire

3 hours ago

Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome

Indeterminate GlobeNewswire

3 hours ago

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants

Indeterminate GlobeNewswire

3 hours ago

Atsena Therapeutics Doses First Patient and Reports Rapid Early Enrollment in Pivotal Trial of ATSN-201 for X-Linked Retinoschisis

Indeterminate GlobeNewswire

3 hours ago

Prolium Bioscience Announces First Patient Dosed in its Multinational, Phase 1/2 Study of PRO-203 in Systemic Sclerosis, and Last Patient, Last Visit in an Investigator-Led Study of PRO-203 in Refractory Lupus Nephritis

Indeterminate GlobeNewswire

3 hours ago

Hexagon Bio Announces Formation of Clinical Advisory Board of Renowned Breast Cancer Experts to Support Development of HEX-360, a Next-Generation HER2-Targeting ADC

Indeterminate GlobeNewswire

3 hours ago

Catheter Precision, Inc. Announces Allowance of Key Intellectual Property

Indeterminate GlobeNewswire

3 hours ago

LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection

Indeterminate GlobeNewswire

3 hours ago

Route 92 Medical Announces First Commercial Cases in Canada

Indeterminate GlobeNewswire

3 hours ago

St. Augustine Dentist Explains Why Replacing Missing Teeth Can Support Long-Term Oral Health

Indeterminate GlobeNewswire

3 hours ago

BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026

Indeterminate GlobeNewswire

3 hours ago

TETmedical Receives FDA Breakthrough Device Designation for NSE-FAST®, the First Rapid Test Designed to Aid in the Diagnosis of Acute Ischemic Stroke

Indeterminate GlobeNewswire

3 hours ago

BrainsWay Reports Favorable Coverage for Accelerated Deep TMS™ Rises to Over 57 Million Covered Lives

Indeterminate GlobeNewswire

3 hours ago

Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026

Indeterminate GlobeNewswire